BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enzomenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enzomenib\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04988555-3087@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enzomenib: Phase 1/2 readout est. (NCT04988555)
DESCRIPTION:Enzomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: A Phase
  1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horize
 n-1)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/enzomenib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04988555
URL:https://assetmemo.bio/drug/enzomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07914855-3087@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Enzomenib: Phase 2 readout est. (NCT07914855)
DESCRIPTION:Enzomenib\, phase 2.\nStudy: Testing the Anti-cancer Drug DSP-5
 336 (Enzomenib) in Prostate Cancer\nEstimated primary completion: 4 Januar
 y 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/enzomenib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0791485
 5
URL:https://assetmemo.bio/drug/enzomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
